Unknown PHASE1 INTERVENTIONAL 3-arm NCT05052970

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

A Phase Ⅰ Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Conditions Relapsed or Refractory Multiple Myeloma

Interventions Bortezomib for Injection Dexamethasone Acetate Tablets Mitoxantrone Hydrochloride Liposome injection

Updated 4 times since 2021 Last updated: Jan 16, 2022 Started: Oct 20, 2021 Primary completion: Apr 20, 2023 Completion: Jun 20, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Relapsed or Refractory Multiple Myeloma, this trial is ongoing. The trial is conducted by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. and has accumulated 4 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Feb 2022 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Oct 2021 — Feb 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Data source: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China